BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

363 related articles for article (PubMed ID: 25956431)

  • 1. Prognostic value of tumor suppressors in osteosarcoma before and after neoadjuvant chemotherapy.
    Robl B; Pauli C; Botter SM; Bode-Lesniewska B; Fuchs B
    BMC Cancer; 2015 May; 15():379. PubMed ID: 25956431
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Excision repair cross-complementation group 1 protein expression predicts survival in patients with high-grade, non-metastatic osteosarcoma treated with neoadjuvant chemotherapy.
    Hattinger CM; Michelacci F; Sella F; Magagnoli G; Benini S; Gambarotti M; Palmerini E; Picci P; Serra M; Ferrari S
    Histopathology; 2015 Sep; 67(3):338-47. PubMed ID: 25600168
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vitronectin significantly influences prognosis in osteosarcoma.
    Shi K; Lan RL; Tao X; Wu CY; Hong HF; Lin JH
    Int J Clin Exp Pathol; 2015; 8(9):11364-71. PubMed ID: 26617861
    [TBL] [Abstract][Full Text] [Related]  

  • 4. P16 expression predicts necrotic response among patients with osteosarcoma receiving neoadjuvant chemotherapy.
    Borys D; Canter RJ; Hoch B; Martinez SR; Tamurian RM; Murphy B; Bishop JW; Horvai A
    Hum Pathol; 2012 Nov; 43(11):1948-54. PubMed ID: 22578565
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interferon-α/β receptor as a prognostic marker in osteosarcoma.
    Kubo T; Shimose S; Matsuo T; Fujimori J; Arihiro K; Ochi M
    J Bone Joint Surg Am; 2011 Mar; 93(6):519-26. PubMed ID: 21411701
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proximal tumor location and fluid-fluid levels on MRI predict resistance to chemotherapy in stage IIB osteosarcoma.
    Jeon DG; Song WS; Cho WH; Kong CB; Cho SH
    Clin Orthop Relat Res; 2014 Jun; 472(6):1911-20. PubMed ID: 24574120
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols.
    Kager L; Zoubek A; Pötschger U; Kastner U; Flege S; Kempf-Bielack B; Branscheid D; Kotz R; Salzer-Kuntschik M; Winkelmann W; Jundt G; Kabisch H; Reichardt P; Jürgens H; Gadner H; Bielack SS;
    J Clin Oncol; 2003 May; 21(10):2011-8. PubMed ID: 12743156
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognosticating metastatic osteosarcoma treated with uniform chemotherapy protocol without high dose methotrexate and delayed metastasectomy: a single center experience of 102 patients.
    Nataraj V; Rastogi S; Khan SA; Sharma MC; Agarwala S; Vishnubhatla S; Bakhshi S
    Clin Transl Oncol; 2016 Sep; 18(9):937-44. PubMed ID: 26742936
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression and prognostic relevance of centromere protein A in primary osteosarcoma.
    Gu XM; Fu J; Feng XJ; Huang X; Wang SM; Chen XF; Zhu MH; Zhang SH
    Pathol Res Pract; 2014 Apr; 210(4):228-33. PubMed ID: 24440098
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The effect of resistance-related proteins on the prognosis and survival of patients with osteosarcoma: an immunohistochemical analysis].
    Ozger H; Eralp L; Atalar AC; Toker B; Esberk Ateş L; Sungur M; Bilgiç B; Ayan I
    Acta Orthop Traumatol Turc; 2009; 43(1):28-34. PubMed ID: 19293613
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Osteosarcoma lung metastases. Survival after chemotherapy and surgery].
    Farfalli GL; Albergo JI; Lobos PA; Smith DE; Streitenberger PD; Pallotta Rodríguez MG; Aponte-Tinao LA
    Medicina (B Aires); 2015; 75(2):87-90. PubMed ID: 25919869
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The β5/focal adhesion kinase/glycogen synthase kinase 3β integrin pathway in high-grade osteosarcoma: a protein expression profile predictive of response to neoadjuvant chemotherapy.
    Le Guellec S; Moyal EC; Filleron T; Delisle MB; Chevreau C; Rubie H; Castex MP; de Gauzy JS; Bonnevialle P; Gomez-Brouchet A
    Hum Pathol; 2013 Oct; 44(10):2149-58. PubMed ID: 23845472
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development and validation of a pretreatment prognostic index to predict death and lung metastases in extremity osteosarcoma.
    Wang B; Tu J; Yin J; Zou C; Wang J; Huang G; Xie X; Shen J
    Oncotarget; 2015 Nov; 6(35):38348-59. PubMed ID: 26435480
    [TBL] [Abstract][Full Text] [Related]  

  • 14. XB130 expression in human osteosarcoma: a clinical and experimental study.
    Wang X; Wang R; Liu Z; Hao F; Huang H; Guo W
    Int J Clin Exp Pathol; 2015; 8(3):2565-73. PubMed ID: 26045762
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improved survival in osteosarcoma patients with atypical low vascularization.
    Kunz P; Fellenberg J; Moskovszky L; Sápi Z; Krenacs T; Machado I; Poeschl J; Lehner B; Szendrõi M; Ruef P; Bohlmann M; Bosch AL; Ewerbeck V; Kinscherf R; Fritzsching B
    Ann Surg Oncol; 2015 Feb; 22(2):489-96. PubMed ID: 25155396
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Caffeine-potentiated chemotherapy for metastatic osteosarcoma.
    Kimura H; Tsuchiya H; Shirai T; Nishida H; Hayashi K; Takeuchi A; Ohnari I; Tomita K
    J Orthop Sci; 2009 Sep; 14(5):556-65. PubMed ID: 19802667
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Expression of hypoxia-inducible factor 1α in osteosarcoma and its value in predicting chemosensitivity].
    Chen Y; Wang CM; Shi YQ; Yang Y
    Zhonghua Zhong Liu Za Zhi; 2012 Dec; 34(12):899-904. PubMed ID: 23336375
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular characterization of the response to chemotherapy in conventional osteosarcomas: predictive value of HSD17B10 and IFITM2.
    Salas S; Jézéquel P; Campion L; Deville JL; Chibon F; Bartoli C; Gentet JC; Charbonnel C; Gouraud W; Voutsinos-Porche B; Brouchet A; Duffaud F; Figarella-Branger D; Bouvier C
    Int J Cancer; 2009 Aug; 125(4):851-60. PubMed ID: 19449377
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic nomogram for predicting the 5-year probability of developing metastasis after neo-adjuvant chemotherapy and definitive surgery for AJCC stage II extremity osteosarcoma.
    Kim MS; Lee SY; Lee TR; Cho WH; Song WS; Koh JS; Lee JA; Yoo JY; Jeon DG
    Ann Oncol; 2009 May; 20(5):955-60. PubMed ID: 19153123
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multiinstitutional phase II study of neoadjuvant chemotherapy for osteosarcoma (NECO study) in Japan: NECO-93J and NECO-95J.
    Iwamoto Y; Tanaka K; Isu K; Kawai A; Tatezaki S; Ishii T; Kushida K; Beppu Y; Usui M; Tateishi A; Furuse K; Minamizaki T; Kawaguchi N; Yamawaki S
    J Orthop Sci; 2009 Jul; 14(4):397-404. PubMed ID: 19662473
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.